Related Experiment Video
Updated: May 23, 2026
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Cerebral amyloid angiopathy
Masahito Yamada1, Hironobu Naiki
1Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Progress in Molecular Biology and Translational Science
|April 10, 2012
Summary
Cerebral amyloid angiopathy (CAA) involves amyloid protein buildup in brain vessels, often linked to Alzheimer's disease. Understanding its causes may lead to new treatments for brain damage and dementia.
Area of Science:
- Neurology
- Pathology
- Biochemistry
Background:
- Cerebral amyloid angiopathy (CAA) is characterized by amyloid protein deposition in cerebral blood vessels.
- It is categorized by the specific amyloid proteins involved, such as amyloid β-protein (Aβ), cystatin C, and others.
- Sporadic Aβ-type CAA frequently affects elderly individuals and those with Alzheimer's disease (AD), contributing to brain lesions and cognitive decline.
Purpose of the Study:
- To elucidate the molecular pathogenesis of cerebral amyloid angiopathy (CAA).
- To explore the origins and clearance mechanisms of cerebrovascular amyloid-beta (Aβ).
- To identify potential therapeutic targets for CAA and related neurological disorders.
Main Methods:
- Review of existing literature on CAA pathogenesis.
- Analysis of proposed mechanisms for Aβ production, degradation, and clearance.
- Examination of the role of perivascular drainage pathways in CAA development.
Main Results:
- Cerebrovascular Aβ is hypothesized to originate primarily within the brain.
- Aβ deposition occurs in vascular basement membranes, potentially influenced by extracellular components.
- Factors promoting CAA include Aβ40 overproduction, reduced Aβ degradation, and impaired perivascular clearance.
Conclusions:
- Understanding CAA's molecular basis is crucial for developing effective therapies.
- Targeting Aβ metabolism and clearance pathways may offer disease-modifying strategies.
- Further research into CAA pathogenesis can advance treatments for dementia and cerebrovascular disorders.
Related Concept Videos
01:22Cerebral Edema ll: Pathophysiology
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:19Cerebral Edema l: Introduction
Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...